CD318-specific CAR T cells

CD318-specific CAR T cells are autologous, genetically engineered T cells modified to express a chimeric antigen receptor (CAR) that specifically recognizes the CD318 antigen (also known as CDCP1) on tumor cells. The therapy is designed as an advanced immunotherapy for cancers with high CD318 expression, particularly pancreatic ductal adenocarcinoma (PDAC). Preclinical studies show robust anti-tumor activity of these CAR T cells in vitro and in vivo, with minimal expression of CD318 in healthy tissues, suggesting a favorable safety profile. The approach uses a GMP-grade lentiviral vector to introduce the CAR construct, followed by ex vivo cell expansion. The most advanced clinical evaluation (ResCPa study) is a first-in-human, phase I/IIa trial for patients with metastatic or locally advanced PDAC refractory to standard treatment, with goals to assess safety, feasibility, and preliminary efficacy. Development is led by a German academic-industry consortium including University Hospital Tübingen and Miltenyi Biotec, among others[1][3].

Other names

CD318-targeted CAR T cellsCD-318-targeted CAR T cellsCD 318-targeted CAR T cellsCD318 CAR T cellsCD-318 CAR T cellsCD 318 CAR T cellsCD318-directed CAR T cellsCD-318-directed CAR T cellsCD 318-directed CAR T cellsCD318-CAR-T cellsCD-318-CAR-T cellsCD 318-CAR-T cells